Doma Perpetual Capital Management LLC Sells Out Pacira BioScienc
Doma Perpetual Capital Management sold all 2.78 million shares of Pacira BioSciences (PCRX) at $36.39 per share on Oct. 8, 2026, eliminating a 16.36% portfolio position. Pacira, a specialty pharmaceutical company, has a $1.45B market cap and trades at a PE ratio of 104.90. GuruFocus values it at $29.42, suggesting a 24% premium. The firm's exit may reflect valuation concerns, as Pacira's stock is deemed modestly overvalued with strong momentum but negative growth trends.
How this was made
The 30-second read
Why it matters
The liquidation represents a sizable signal to the market about perceived valuation risk, potentially prompting short‑term price weakness.
Market read
Fund exit is a primary disclosure that may influence short‑term PCRX trading and signals valuation concerns to value‑oriented investors.
What to watch
Fund may be reallocating capital to new ideas; the exit does not necessarily reflect negative outlook on the drug pipeline.
Background
The article details a 13F‑style filing showing a concentrated hedge fund exiting its entire stake in Pacira BioSciences.
Ticker impact
Doma Perpetual Capital Management sold its entire 2,777,794‑share position in Pacira BioSciences at $36.39 per share, removing the stock from its portfolio.
likely downward pressure as the market absorbs the large sell‑off.
A 16% portfolio impact from a concentrated fund exit is material; such moves often precede short‑term price weakness.
Market effects
Reduces healthcare exposure for the fund, may prompt other value investors to reassess PCRX.
U.S. biotech sector sees modest attention; no broader regional effect.
Limited to investors tracking guru activity; no global macro impact.
Counterpoint
The sell‑off could be a tactical move unrelated to fundamentals; PCRX may still rally on momentum.
Key entities
- investment_firmDoma Perpetual Capital Management LLC
Miami‑based fund with $431 M AUM that fully exited PCRX.
- companyPacira BioSciences Inc
U.S. specialty pharma focused on non‑opioid pain management, ticker PCRX.
